InsidersTradesSigma
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Explore the detailed record of transactions filed by Kellen Scott, 首席财务官. Director active across 1 company, notably DiaMedica Therapeutics Inc.. Cumulatively, 2 reports have been recorded. Breakdown: 2 buys · 0 sell. Total volume traded: €62k. Activity tracked since 16 August 2021. The latest transaction was filed on 23 June 2023 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 条申报中的 2 条
Kellen Scott serves as the Chief Financial Officer and Secretary of DiaMedica Therapeutics Inc. In this role, he is responsible for the financial management of the company, including financial planning, risk management, and financial compliance. Kellen brings significant expertise in finance and plays a key role in DiaMedica's financial strategy, a company focused on developing treatments for neurological diseases.